This is a Validated Antibody Database (VAD) review about mouse Cd274, based on 162 published articles (read how Labome selects the articles), using Cd274 antibody in all methods. It is aimed to help Labome visitors find the most suited Cd274 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Cd274 synonym: A530045L16Rik; B7h1; Pdcd1l1; Pdcd1lg1; Pdl1

Knockout validation
Abcam
domestic rabbit monoclonal (EPR20529)
  • western blot knockout validation; mouse; 1:100; fig 5e
Abcam Cd274 antibody (Abcam, ab213480) was used in western blot knockout validation on mouse samples at 1:100 (fig 5e). iScience (2022) ncbi
Abcam
domestic rabbit monoclonal (EPR20529)
  • immunohistochemistry knockout validation; mouse; fig 8c
  • flow cytometry; mouse; fig s8b
Abcam Cd274 antibody (Abcam, ab213480) was used in immunohistochemistry knockout validation on mouse samples (fig 8c) and in flow cytometry on mouse samples (fig s8b). Mol Cancer (2021) ncbi
BioLegend
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 1a, 1c, s2b, s2c
BioLegend Cd274 antibody (Biolegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 1a, 1c, s2b, s2c). Nat Commun (2022) ncbi
rat monoclonal (10F.9G2)
  • immunohistochemistry - paraffin section; mouse; 1:100; fig s6n
BioLegend Cd274 antibody (Biolegend, 124302) was used in immunohistochemistry - paraffin section on mouse samples at 1:100 (fig s6n). Nat Commun (2022) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 2l, 7a
BioLegend Cd274 antibody (BioLegend, 124308) was used in flow cytometry on mouse samples (fig 2l, 7a). J Immunother Cancer (2022) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; fig 7k
  • flow cytometry; human; loading ...; fig 7j
BioLegend Cd274 antibody (BioLegend, 124308) was used in flow cytometry on mouse samples (fig 7k) and in flow cytometry on human samples (fig 7j). J Immunother Cancer (2022) ncbi
rat monoclonal (10F.9G2)
  • immunohistochemistry - paraffin section; mouse; fig s2
BioLegend Cd274 antibody (BioLegend, 10 F.9G2) was used in immunohistochemistry - paraffin section on mouse samples (fig s2). Oncoimmunology (2022) ncbi
rat monoclonal (10F.9G2)
  • immunohistochemistry; mouse; loading ...; fig 4a
BioLegend Cd274 antibody (Biolegend, 124311) was used in immunohistochemistry on mouse samples (fig 4a). Nat Commun (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:200; loading ...
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples at 1:200. J Immunother Cancer (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:100
BioLegend Cd274 antibody (BioLegend, 124313) was used in flow cytometry on mouse samples at 1:100. Nat Commun (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:100; loading ...
BioLegend Cd274 antibody (BioLegend, 124313) was used in flow cytometry on mouse samples at 1:100. Commun Biol (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:200; loading ...; fig 2f
BioLegend Cd274 antibody (Biolegend, 10F.9G2) was used in flow cytometry on mouse samples at 1:200 (fig 2f). Nat Commun (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; fig 1h, 5j
BioLegend Cd274 antibody (Biolegend, 124305) was used in flow cytometry on mouse samples (fig 1h, 5j). Cell Death Dis (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 5k
BioLegend Cd274 antibody (Biolegend, 124312) was used in flow cytometry on mouse samples (fig 5k). J Immunother Cancer (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:200; loading ...
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples at 1:200. Cancer Res (2021) ncbi
rat monoclonal (10F.9G2)
  • mass cytometry; mouse
BioLegend Cd274 antibody (Biolegend, 124302) was used in mass cytometry on mouse samples . Cancer Cell (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:200; fig s6h
BioLegend Cd274 antibody (Biolegend, 124319) was used in flow cytometry on mouse samples at 1:200 (fig s6h). Cell Rep (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 5f
BioLegend Cd274 antibody (Biolegend, 124312) was used in flow cytometry on mouse samples (fig 5f). J Immunother Cancer (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig s9c
BioLegend Cd274 antibody (Biolegend, 124331) was used in flow cytometry on mouse samples (fig s9c). Mol Cancer (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; human; 1:1000; loading ...; fig e6b
BioLegend Cd274 antibody (Biolegend, 124321) was used in flow cytometry on human samples at 1:1000 (fig e6b). Nat Cancer (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; human; loading ...
BioLegend Cd274 antibody (Biolegend, 124307) was used in flow cytometry on human samples . J Immunother Cancer (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...
BioLegend Cd274 antibody (Biolegend, 124324) was used in flow cytometry on mouse samples . Cell (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; fig 2a
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 2a). JCI Insight (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:250; loading ...
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples at 1:250. Sci Adv (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 5i
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 5i). Front Immunol (2020) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:250; loading ...; fig 2d
BioLegend Cd274 antibody (BioLegend, 124308) was used in flow cytometry on mouse samples at 1:250 (fig 2d). Cancer Res (2021) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; ; fig 4b
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in blocking or activating experiments on mouse samples at (fig 4b). FEBS Open Bio (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; fig 6i
BioLegend Cd274 antibody (Biolegend, 124314) was used in flow cytometry on mouse samples (fig 6i). Sci Rep (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; fig 4b
BioLegend Cd274 antibody (Biolegend, 124312) was used in flow cytometry on mouse samples (fig 4b). Cancer Sci (2021) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...
BioLegend Cd274 antibody (Biolegend, 124313) was used in flow cytometry on mouse samples . Nat Commun (2020) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 2a
BioLegend Cd274 antibody (Biolegend, 10 F .9G2) was used in flow cytometry on mouse samples (fig 2a). J Immunother Cancer (2020) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:100
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples at 1:100. Nature (2020) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:100; loading ...; fig 4, 5, s8, s9
BioLegend Cd274 antibody (eBioscience, 124308) was used in flow cytometry on mouse samples at 1:100 (fig 4, 5, s8, s9). Nat Commun (2020) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig s4
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig s4). Sci Adv (2020) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig s3a, s3b, s3c, s4a
BioLegend Cd274 antibody (BioLegend, 124308) was used in flow cytometry on mouse samples (fig s3a, s3b, s3c, s4a). Cancers (Basel) (2020) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 6s2
BioLegend Cd274 antibody (Biolegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 6s2). elife (2020) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; fig 1e
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 1e). Acta Neuropathol Commun (2020) ncbi
rat monoclonal (10F.9G2)
  • mass cytometry; mouse; 3 ug/ml; loading ...; fig 5d
BioLegend Cd274 antibody (Biolegend, 10F.9G2) was used in mass cytometry on mouse samples at 3 ug/ml (fig 5d). Science (2019) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 6c
BioLegend Cd274 antibody (BioLegend, 124313) was used in flow cytometry on mouse samples (fig 6c). Cell (2019) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 3d
BioLegend Cd274 antibody (BioLegend, 124312) was used in flow cytometry on mouse samples (fig 3d). J Exp Med (2020) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 2h
BioLegend Cd274 antibody (Biolegend, 124312) was used in flow cytometry on mouse samples (fig 2h). Oncoimmunology (2019) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig s2d
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig s2d). Nature (2019) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 1b
BioLegend Cd274 antibody (Biolegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 1b). Front Immunol (2019) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:400; loading ...; fig 3f
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples at 1:400 (fig 3f). Nat Med (2019) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig s1g
BioLegend Cd274 antibody (Biolegend, 124307) was used in flow cytometry on mouse samples (fig s1g). Cell (2019) ncbi
rat monoclonal (MIH7)
  • flow cytometry; mouse; loading ...; fig 7c
BioLegend Cd274 antibody (BioLegend, MIH7) was used in flow cytometry on mouse samples (fig 7c). J Clin Invest (2019) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; human; loading ...; fig s1e
BioLegend Cd274 antibody (BioLegend, 124321) was used in flow cytometry on human samples (fig s1e). Cell Rep (2018) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 4a
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 4a). JCI Insight (2018) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:150; loading ...; fig 3b
BioLegend Cd274 antibody (BioLegend, 124308) was used in flow cytometry on mouse samples at 1:150 (fig 3b). Br J Cancer (2019) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig s1b
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig s1b). J Clin Invest (2019) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:200; loading ...; fig 4h
BioLegend Cd274 antibody (BioLegend, 10-F.9G2) was used in flow cytometry on mouse samples at 1:200 (fig 4h). Nat Commun (2018) ncbi
rat monoclonal (10F.9G2)
  • immunohistochemistry - frozen section; mouse; loading ...; fig 6
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in immunohistochemistry - frozen section on mouse samples (fig 6). J Clin Invest (2018) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 1a
BioLegend Cd274 antibody (BioLegend, 124307) was used in flow cytometry on mouse samples (fig 1a). Immunity (2018) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig s7g
BioLegend Cd274 antibody (Biolegend, 124319) was used in flow cytometry on mouse samples (fig s7g). Immunity (2018) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; human; loading ...; fig s1a
BioLegend Cd274 antibody (Biolegend, 124314) was used in flow cytometry on human samples (fig s1a). Immunity (2018) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig s6a
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig s6a). J Clin Invest (2018) ncbi
rat monoclonal (10F.9G2)
  • western blot; mouse; 1:100; loading ...; fig 6c
BioLegend Cd274 antibody (BioLegend, 124315) was used in western blot on mouse samples at 1:100 (fig 6c). Nat Commun (2018) ncbi
rat monoclonal (10F.9G2)
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used . Oncoimmunology (2018) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; human; 1:200; loading ...; fig s4f
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on human samples at 1:200 (fig s4f). J Clin Invest (2018) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 3d
BioLegend Cd274 antibody (bioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 3d). J Exp Med (2018) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:200; loading ...; fig s1a
BioLegend Cd274 antibody (BioLegend, 124312) was used in flow cytometry on mouse samples at 1:200 (fig s1a). J Clin Invest (2018) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:100; loading ...; fig 4b
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples at 1:100 (fig 4b). Nat Commun (2017) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 1d
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 1d). Immunology (2017) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; fig 3a
In order to elucidate how schistosome-induced B cells protect against allergic airway inflammation, BioLegend Cd274 antibody (Biolegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 3a). Int J Parasitol (2017) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:300; loading ...; fig 1a, 2b
In order to test if oncolytic poxvirus treatment improves anti-PD-L1 immunotherapy, BioLegend Cd274 antibody (BioLegend, 124312) was used in flow cytometry on mouse samples at 1:300 (fig 1a, 2b). Nat Commun (2017) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 2b
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 2b). Immunology (2017) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 1c
In order to study a mouse model of anti-human PD-L1 for developing new cancer treatments., BioLegend Cd274 antibody (Biolegend, 10 F.9G2) was used in flow cytometry on mouse samples (fig 1c). Sci Rep (2017) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 6c
In order to discover that SIRPalpha is highly expressed in human renal cell carcinoma and melanoma, BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 6c). JCI Insight (2017) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:100; loading ...; fig S5
In order to find that C-type lectin dendritic cell immunoreceptor is required to modulate lung inflammation and bacterial burden in tuberculosis, BioLegend Cd274 antibody (Biolegend, 10F.9G2) was used in flow cytometry on mouse samples at 1:100 (fig S5). Proc Natl Acad Sci U S A (2017) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig s8b
In order to explore how apoptotic intestinal epithelial cells are processed and sampled, BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig s8b). Nature (2016) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 4c
  • flow cytometry; human; loading ...; fig 4c
In order to show that R848-mediated suppression of experimental asthma is IL-27-dependent, BioLegend Cd274 antibody (Biolegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 4c) and in flow cytometry on human samples (fig 4c). J Immunol (2016) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:800; loading ...; fig 3a
In order to test how inhibiting autophagy impacts antitumor immune responses in immune-competent mouse models of melanoma and mammary cancer, BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples at 1:800 (fig 3a). J Clin Invest (2016) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig s4e
In order to study T cell migration in inflammatory demyelinating lesions confined to optic nerves and spinal cord, BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig s4e). Proc Natl Acad Sci U S A (2016) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; human; 1:100; fig 1
  • flow cytometry; mouse; 1:100; fig 1
BioLegend Cd274 antibody (Biolegend, 124319) was used in flow cytometry on human samples at 1:100 (fig 1) and in flow cytometry on mouse samples at 1:100 (fig 1). Nat Commun (2016) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; fig 4
In order to test if a diet high in fats affects the development of respiratory tolerance, BioLegend Cd274 antibody (Biolegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 4). PLoS ONE (2016) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; fig 6
  • flow cytometry; mouse; fig 5
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in blocking or activating experiments on mouse samples (fig 6) and in flow cytometry on mouse samples (fig 5). Clin Cancer Res (2017) ncbi
rat monoclonal (10F.9G2)
In order to develop a protocol for differentiation of retinal pigment epithelium from mouse induced pluripotent stem cells, BioLegend Cd274 antibody (BioLegend, 124307) was used . PLoS ONE (2016) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 4m
In order to report how the parallel networks of necroptosis-induced CXCL1 and Mincle signaling promote pancreatic ductal adenocarcinoma progression, BioLegend Cd274 antibody (Biolegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 4m). Nature (2016) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; fig 2e
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 2e). Gastroenterology (2016) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 3e
In order to compare the capacity of induced T regulatory and T helper 17 cells to develop in a T cell model of colitis, BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 3e). J Immunol (2016) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; fig 1
BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 1). PLoS ONE (2016) ncbi
rat monoclonal (10F.9G2)
  • immunohistochemistry - paraffin section; mouse; 1:150; fig 4b
  • flow cytometry; mouse
In order to discuss models of squamous lung tumors to test therapeutic regimens, BioLegend Cd274 antibody (Biolegend, 10F.9G2) was used in immunohistochemistry - paraffin section on mouse samples at 1:150 (fig 4b) and in flow cytometry on mouse samples . J Thorac Oncol (2016) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; 1:200; fig 5
BioLegend Cd274 antibody (Biolegend, 10F.9G2) was used in flow cytometry on mouse samples at 1:200 (fig 5). Nat Commun (2016) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; fig 6
BioLegend Cd274 antibody (BioLegend, 124313) was used in flow cytometry on mouse samples (fig 6). Oncotarget (2015) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; loading ...; fig 5a
BioLegend Cd274 antibody (Biolegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 5a). Cancer Res (2015) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; fig 3
In order to assess whether programmed cell death 1 regulates psoriasiform dermatitis in mice, BioLegend Cd274 antibody (BioLegend, 10F.9G2) was used in flow cytometry on mouse samples (fig 3). J Immunol (2015) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; mouse; fig 1
In order to study engineered anti-melanoma vaccines that modulate cytokine priming and silence PD-L1 simultaneously by use of ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy, BioLegend Cd274 antibody (BioLegend, 124305) was used in flow cytometry on mouse samples (fig 1). Oncoimmunology (2014) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; fig 5
BioLegend Cd274 antibody (Biolegend, 10F.9G2) was used in blocking or activating experiments on mouse samples (fig 5). Nat Commun (2015) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; fig 6
BioLegend Cd274 antibody (BioLegend and BioXcell, 10F.9G2) was used in blocking or activating experiments on mouse samples (fig 6). J Immunol (2015) ncbi
rat monoclonal (10F.9G2)
BioLegend Cd274 antibody (BioLegend, 124301) was used . Infect Immun (2015) ncbi
rat monoclonal (10F.9G2)
  • flow cytometry; human; loading ...; fig 1
In order to discuss the importance of assessing immune competence in cancer patients, BioLegend Cd274 antibody (Biolegend, 10F.9G2) was used in flow cytometry on human samples (fig 1). Cancer Immunol Immunother (2014) ncbi
Invitrogen
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...; fig s1b, s4g, s7a
Invitrogen Cd274 antibody (Thermo Fisher, 78-5982-82) was used in flow cytometry on mouse samples (fig s1b, s4g, s7a). Sci Adv (2022) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...; fig s3
Invitrogen Cd274 antibody (eBioscience, 25-5982-80) was used in flow cytometry on mouse samples (fig s3). Cell Rep (2022) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse
Invitrogen Cd274 antibody (eBioscience, 12-5982-82) was used in flow cytometry on mouse samples . Theranostics (2021) ncbi
rat monoclonal (MIH5)
  • immunohistochemistry - paraffin section; mouse; 1:50; loading ...; fig 5a
Invitrogen Cd274 antibody (eBioscience, 14-5982-82) was used in immunohistochemistry - paraffin section on mouse samples at 1:50 (fig 5a). Front Oncol (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - frozen section; mouse; 1:100; loading ...; fig 3a
Invitrogen Cd274 antibody (Invitrogen, PA5-20343) was used in immunohistochemistry - frozen section on mouse samples at 1:100 (fig 3a). Cell Mol Gastroenterol Hepatol (2021) ncbi
rat monoclonal (MIH5)
  • blocking or activating experiments; human; 10 ug/ml; loading ...; fig 3e
Invitrogen Cd274 antibody (Invitrogen, 16-5982-82) was used in blocking or activating experiments on human samples at 10 ug/ml (fig 3e). J Immunother Cancer (2021) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...; fig 4a
Invitrogen Cd274 antibody (eBiosciences, 64-5982-82) was used in flow cytometry on mouse samples (fig 4a). Biomedicines (2020) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse
Invitrogen Cd274 antibody (eBioscience, MIH5) was used in flow cytometry on mouse samples . Mucosal Immunol (2021) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; 1:100; loading ...; fig 4, 5, s8, s9
Invitrogen Cd274 antibody (eBioscience, 25-5982-82) was used in flow cytometry on mouse samples at 1:100 (fig 4, 5, s8, s9). Nat Commun (2020) ncbi
rat monoclonal (MIH5)
  • blocking or activating experiments; mouse; 5 ug/ml; loading ...; fig 3b
Invitrogen Cd274 antibody (eBioscience, 16-5982-85) was used in blocking or activating experiments on mouse samples at 5 ug/ml (fig 3b). Aging (Albany NY) (2020) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...; fig s6
Invitrogen Cd274 antibody (ThermoFisher, 78-5982-82) was used in flow cytometry on mouse samples (fig s6). Cell Rep (2019) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; 1:100; loading ...; fig s6a, s6b
Invitrogen Cd274 antibody (eBioscience, 17598282) was used in flow cytometry on mouse samples at 1:100 (fig s6a, s6b). Nat Commun (2019) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...; fig 6c
Invitrogen Cd274 antibody (eBioscience, 46-5982-82) was used in flow cytometry on mouse samples (fig 6c). Nat Commun (2018) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; fig s3
Invitrogen Cd274 antibody (Thermo Fisher, 12-5982-81) was used in flow cytometry on mouse samples (fig s3). Cell (2018) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; fig 2f
Invitrogen Cd274 antibody (eBioscience, 13-5982-81) was used in flow cytometry on mouse samples (fig 2f). Cell (2018) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...; fig s1a
Invitrogen Cd274 antibody (eBioscience, M1H5) was used in flow cytometry on mouse samples (fig s1a). Cancer Immunol Immunother (2019) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...; fig e5c
Invitrogen Cd274 antibody (eBiosciences, MIH5) was used in flow cytometry on mouse samples (fig e5c). Nature (2018) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; 1:300; loading ...; fig 5a
In order to test if oncolytic poxvirus treatment improves anti-PD-L1 immunotherapy, Invitrogen Cd274 antibody (eBioscience, 13-5982-85) was used in flow cytometry on mouse samples at 1:300 (fig 5a). Nat Commun (2017) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...
In order to test if TRAIL/TRAIL-R signaling in cancer cells alters the immune microenvironment, Invitrogen Cd274 antibody (eBioscience, 12-5982-82) was used in flow cytometry on mouse samples . Mol Cell (2017) ncbi
domestic rabbit polyclonal
  • immunoprecipitation; rat; loading ...; fig 2c
  • immunocytochemistry; rat; loading ...; fig 5b
  • western blot; rat; loading ...; fig 3b
In order to assess the critical role of programmed death protein 1/programmed death-ligand 1 in the polarization of microglia during intracerebral hemorrhage-induced secondary brain injury, Invitrogen Cd274 antibody (Thermo Fisher, PA5-20343) was used in immunoprecipitation on rat samples (fig 2c), in immunocytochemistry on rat samples (fig 5b) and in western blot on rat samples (fig 3b). J Neuroinflammation (2017) ncbi
rat monoclonal (1-111A)
  • flow cytometry; mouse; loading ...; fig 1f
In order to study the role of FAP in the mouse immune response against influenza., Invitrogen Cd274 antibody (eBioscience, 13-9971-81) was used in flow cytometry on mouse samples (fig 1f). PLoS ONE (2017) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...; fig s5
In order to characterize mitochondrial changes in T cells due to PD-1 blockade therapy, Invitrogen Cd274 antibody (eBioscience, M1H5) was used in flow cytometry on mouse samples (fig s5). Proc Natl Acad Sci U S A (2017) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...; fig 7e
In order to examine skin dendritic cells from mice exposed to two different Th2 stimuli, Invitrogen Cd274 antibody (eBioscience, MIH5) was used in flow cytometry on mouse samples (fig 7e). J Exp Med (2017) ncbi
rat monoclonal (MIH5)
  • immunohistochemistry; mouse; 1:100; loading ...; fig 5b
  • western blot; human; 1:1000; fig 5g
In order to discuss the role of myeloid cells in pancreatic cancer pathogenesis, Invitrogen Cd274 antibody (eBioscience, 14-5982) was used in immunohistochemistry on mouse samples at 1:100 (fig 5b) and in western blot on human samples at 1:1000 (fig 5g). Gut (2017) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...; fig 1
In order to report the effects of PD-L1 modulation of T cell function in graft-versus-host disease, Invitrogen Cd274 antibody (eBioscience, MIH5) was used in flow cytometry on mouse samples (fig 1). J Clin Invest (2016) ncbi
rat monoclonal (MIH5)
  • immunocytochemistry; mouse; 1:500; fig 1
Invitrogen Cd274 antibody (eBioscience, MIH5) was used in immunocytochemistry on mouse samples at 1:500 (fig 1). PLoS ONE (2016) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse
Invitrogen Cd274 antibody (eBioscience, MIH5) was used in flow cytometry on mouse samples . J Immunol (2014) ncbi
rat monoclonal (MIH5)
  • flow cytometry; human
Invitrogen Cd274 antibody (eBioscience, MIH5) was used in flow cytometry on human samples . Cancer Res (2014) ncbi
rat monoclonal (MIH5)
  • flow cytometry; human
Invitrogen Cd274 antibody (eBioscience, 12-5982-82) was used in flow cytometry on human samples . J Immunol (2014) ncbi
rat monoclonal (MIH5)
  • western blot; mouse; fig 1
Invitrogen Cd274 antibody (eBiosciences, #16-5982-81) was used in western blot on mouse samples (fig 1). Cancer Res (2014) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; fig 3
In order to examine the contribution of PD-L1 or PD-L2 to limiting stroke severity, Invitrogen Cd274 antibody (eBioscience, MIH5) was used in flow cytometry on mouse samples (fig 3). J Neuroinflammation (2013) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; fig s2
Invitrogen Cd274 antibody (Ebioscience, MIH5) was used in flow cytometry on mouse samples (fig s2). PLoS Pathog (2013) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; fig 7
In order to test if upregulation of major histocompatibility complex class II and costimulatory molecules in the retina contributes to the regulation of CD4 T cells, Invitrogen Cd274 antibody (eBiosciences, M1H5) was used in flow cytometry on mouse samples (fig 7). Infect Immun (2010) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse
In order to determine the contribution of the host's circulating progenitor cells after implantation of mesenchymal stem cells/bioscaffold combinations in repairing bone defects, Invitrogen Cd274 antibody (eBioscience, MIH5) was used in flow cytometry on mouse samples . Tissue Eng Part A (2009) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse
In order to assess the role of T regulatory cells in Th2-type airway inflammation in mice, Invitrogen Cd274 antibody (eBioscience, M1H5) was used in flow cytometry on mouse samples . J Immunol (2008) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse
Invitrogen Cd274 antibody (eBioscience, MIH5) was used in flow cytometry on mouse samples . Cell Res (2008) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; fig 5a
In order to study the effect of Lactobacillus acidophilus strain L-92 on antigen-stimulated T cell responses in vitro and in vivo, Invitrogen Cd274 antibody (e-Bioscience, MIH5) was used in flow cytometry on mouse samples (fig 5a). Immunobiology (2008) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse
In order to investigate the roles of PD-L1 and PD-L2 expressed by dendritic cells in naive CD4+ T cell activation, Invitrogen Cd274 antibody (eBioscience, MIH5) was used in flow cytometry on mouse samples . Eur J Immunol (2006) ncbi
rat monoclonal (MIH5)
  • blocking or activating experiments; mouse; 10 ug/ml
  • immunohistochemistry - frozen section; mouse
  • flow cytometry; mouse
  • western blot; mouse
Invitrogen Cd274 antibody (eBioscience, MIH5) was used in blocking or activating experiments on mouse samples at 10 ug/ml, in immunohistochemistry - frozen section on mouse samples , in flow cytometry on mouse samples and in western blot on mouse samples . Nephrol Dial Transplant (2004) ncbi
rat monoclonal (MIH5)
  • blocking or activating experiments; mouse
  • flow cytometry; mouse
In order to elucidate how Schistosoma mansoni suppresses T cell activation, Invitrogen Cd274 antibody (eBiosciences, MIH5) was used in blocking or activating experiments on mouse samples and in flow cytometry on mouse samples . J Immunol (2004) ncbi
Abcam
domestic rabbit monoclonal (EPR20529)
  • western blot knockout validation; mouse; 1:100; fig 5e
Abcam Cd274 antibody (Abcam, ab213480) was used in western blot knockout validation on mouse samples at 1:100 (fig 5e). iScience (2022) ncbi
domestic rabbit monoclonal (EPR20529)
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 5f
Abcam Cd274 antibody (Abcam, ab213480) was used in immunohistochemistry - paraffin section on mouse samples (fig 5f). Cell Rep (2022) ncbi
domestic rabbit monoclonal (EPR20529)
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 4f
Abcam Cd274 antibody (Abcam, 213480) was used in immunohistochemistry - paraffin section on mouse samples (fig 4f). J Immunother Cancer (2022) ncbi
domestic rabbit monoclonal (EPR20529)
  • western blot; mouse; 1:1000; loading ...; fig 6f
Abcam Cd274 antibody (Abcam, ab213480) was used in western blot on mouse samples at 1:1000 (fig 6f). Nat Commun (2022) ncbi
domestic rabbit monoclonal (EPR20529)
  • western blot; mouse; 1:2000; loading ...; fig 1h, 1n, s1c
Abcam Cd274 antibody (Abcam, ab213480) was used in western blot on mouse samples at 1:2000 (fig 1h, 1n, s1c). Nat Commun (2022) ncbi
domestic rabbit polyclonal
  • blocking or activating experiments; mouse; fig 4b
  • immunohistochemistry - frozen section; mouse; 1:200; loading ...; fig 1a
  • western blot; mouse; 1:200; loading ...; fig 1c
Abcam Cd274 antibody (Abcam, ab233482) was used in blocking or activating experiments on mouse samples (fig 4b), in immunohistochemistry - frozen section on mouse samples at 1:200 (fig 1a) and in western blot on mouse samples at 1:200 (fig 1c). J Neuroinflammation (2022) ncbi
domestic rabbit monoclonal (EPR20529)
  • western blot; human; 1:1000; loading ...; fig 2c
  • immunohistochemistry - paraffin section; mouse; 1:200; loading ...; fig 1a
  • western blot; mouse; 1:1000; loading ...; fig 2f
Abcam Cd274 antibody (Abcam, ab213480) was used in western blot on human samples at 1:1000 (fig 2c), in immunohistochemistry - paraffin section on mouse samples at 1:200 (fig 1a) and in western blot on mouse samples at 1:1000 (fig 2f). Front Cell Dev Biol (2021) ncbi
domestic rabbit monoclonal (EPR20529)
  • immunohistochemistry; mouse; 1:50; loading ...; fig 4b
Abcam Cd274 antibody (Abcam, ab213480) was used in immunohistochemistry on mouse samples at 1:50 (fig 4b). Theranostics (2021) ncbi
domestic rabbit monoclonal (EPR20529)
  • immunohistochemistry knockout validation; mouse; fig 8c
  • flow cytometry; mouse; fig s8b
Abcam Cd274 antibody (Abcam, ab213480) was used in immunohistochemistry knockout validation on mouse samples (fig 8c) and in flow cytometry on mouse samples (fig s8b). Mol Cancer (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; 1:200; fig s3f
Abcam Cd274 antibody (Abcam, ab233482) was used in immunohistochemistry - paraffin section on mouse samples at 1:200 (fig s3f). Cell Death Dis (2021) ncbi
domestic rabbit monoclonal (EPR20529)
  • western blot; mouse; 1:2000; loading ...; fig 2a
Abcam Cd274 antibody (Abcam, ab213480) was used in western blot on mouse samples at 1:2000 (fig 2a). Front Oncol (2021) ncbi
domestic rabbit monoclonal (EPR20529)
  • western blot; mouse; loading ...; fig 3c
Abcam Cd274 antibody (Abcam, ab213480) was used in western blot on mouse samples (fig 3c). Adv Sci (Weinh) (2021) ncbi
domestic rabbit monoclonal (EPR20529)
  • western blot; human; 1:3000; loading ...; fig 2a
Abcam Cd274 antibody (Abcam, ab213480) was used in western blot on human samples at 1:3000 (fig 2a). FEBS Open Bio (2021) ncbi
domestic rabbit monoclonal (EPR20529)
  • western blot; mouse; loading ...; fig 3a
Abcam Cd274 antibody (Abcam, AB213480) was used in western blot on mouse samples (fig 3a). Cell (2019) ncbi
Bio X Cell
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; 1 ug/ml; loading ...; fig 6a
Bio X Cell Cd274 antibody (BioXCell, 10F.9G2) was used in blocking or activating experiments on mouse samples at 1 ug/ml (fig 6a). Nat Commun (2022) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; fig 6a
Bio X Cell Cd274 antibody (InVivoMab, 10F.9G2) was used in blocking or activating experiments on mouse samples (fig 6a). Mol Ther Oncolytics (2022) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; ; fig 7h
Bio X Cell Cd274 antibody (BioXCell, BE0101) was used in blocking or activating experiments on mouse samples at (fig 7h). Cell Rep (2021) ncbi
rat monoclonal (10F.9G2)
  • other; mouse
Bio X Cell Cd274 antibody (BioXcell, 10F.9G2) was used in other on mouse samples . Front Immunol (2020) ncbi
rat monoclonal (10F.9G2)
  • other; mouse
Bio X Cell Cd274 antibody (BioXcell, 10F.9G2) was used in other on mouse samples . Neurology (2021) ncbi
rat monoclonal (10F.9G2)
  • other; mouse; loading ...
Bio X Cell Cd274 antibody (BioXcell, 10F.9G2) was used in other on mouse samples . Nat Commun (2020) ncbi
rat monoclonal (10F.9G2)
  • immunohistochemistry; mouse; loading ...; fig 3d
Bio X Cell Cd274 antibody (Bioxcell, 10F.9G2) was used in immunohistochemistry on mouse samples (fig 3d). Nat Commun (2020) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; ; fig 3a
Bio X Cell Cd274 antibody (Bio X Cell, BP0101) was used in blocking or activating experiments on mouse samples at (fig 3a). Oncoimmunology (2020) ncbi
rat monoclonal (10F.9G2)
  • western blot; mouse; loading ...; fig s6e
Bio X Cell Cd274 antibody (Bio X Cell, BE0101) was used in western blot on mouse samples (fig s6e). J Clin Invest (2020) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; fig 4b
Bio X Cell Cd274 antibody (Bio X Cell, BE0101) was used in blocking or activating experiments on mouse samples (fig 4b). Aging (Albany NY) (2020) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; loading ...; fig 3c
Bio X Cell Cd274 antibody (BioXcell, 10F.9G2) was used in blocking or activating experiments on mouse samples (fig 3c). Nature (2019) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; fig 2c
Bio X Cell Cd274 antibody (BIOXCELL, 10F.9G2) was used in blocking or activating experiments on mouse samples (fig 2c). Nat Commun (2019) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; ; fig 3b
Bio X Cell Cd274 antibody (BXCell, BE0101) was used in blocking or activating experiments on mouse samples at (fig 3b). Br J Cancer (2019) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; loading ...; fig 5a
Bio X Cell Cd274 antibody (BioXCell, 10F.9G2) was used in blocking or activating experiments on mouse samples (fig 5a). J Clin Invest (2018) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; loading ...; fig 4c
Bio X Cell Cd274 antibody (BioXcell, 10F.9G2) was used in blocking or activating experiments on mouse samples (fig 4c). Nat Commun (2017) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; loading ...; fig 2d
Bio X Cell Cd274 antibody (BioXCell, 10F.9G2) was used in blocking or activating experiments on mouse samples (fig 2d). Proc Natl Acad Sci U S A (2016) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; loading ...; fig 1c
Bio X Cell Cd274 antibody (BioXcell, 10F.9G2) was used in blocking or activating experiments on mouse samples (fig 1c). Oncoimmunology (2016) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; loading ...; fig 2f
Bio X Cell Cd274 antibody (Bio X Cell, clone 10F.9G2) was used in blocking or activating experiments on mouse samples (fig 2f). J Immunol (2015) ncbi
rat monoclonal (10F.9G2)
  • blocking or activating experiments; mouse; loading ...; fig s3
In order to test if blocking several checkpoint receptors boosts anti-tumor immunity in a low-dose, lymphodepleting whole body radiation model, Bio X Cell Cd274 antibody (BioXCell, 10F.9G2) was used in blocking or activating experiments on mouse samples (fig s3). J Immunother Cancer (2015) ncbi
R&D Systems
domestic goat polyclonal
  • immunohistochemistry - paraffin section; mouse; 1:100; fig s7f
R&D Systems Cd274 antibody (R&D Systems, AF1019) was used in immunohistochemistry - paraffin section on mouse samples at 1:100 (fig s7f). Cell Rep (2022) ncbi
domestic goat polyclonal
  • western blot; mouse; loading ...; fig 10p, 10q
R&D Systems Cd274 antibody (R&D, AF1019) was used in western blot on mouse samples (fig 10p, 10q). Cell Mol Gastroenterol Hepatol (2021) ncbi
Novus Biologicals
domestic rabbit polyclonal (6H12)
  • immunohistochemistry - paraffin section; mouse; fig 6
Novus Biologicals Cd274 antibody (Novus, NBP1-76769) was used in immunohistochemistry - paraffin section on mouse samples (fig 6). Front Cell Dev Biol (2021) ncbi
domestic rabbit polyclonal (6H12)
  • western blot; human; fig 4g
Novus Biologicals Cd274 antibody (Novus Biologicals, NBP1-76769) was used in western blot on human samples (fig 4g). EMBO Mol Med (2021) ncbi
Cell Signaling Technology
domestic rabbit monoclonal (D5V3B)
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 8g
Cell Signaling Technology Cd274 antibody (Cell Signaling, 64988) was used in immunohistochemistry - paraffin section on mouse samples (fig 8g). J Immunother Cancer (2022) ncbi
domestic rabbit monoclonal (D5V3B)
  • immunohistochemistry; mouse; loading ...
Cell Signaling Technology Cd274 antibody (Cell Signaling Technology, D5V3B) was used in immunohistochemistry on mouse samples . Nat Commun (2020) ncbi
domestic rabbit monoclonal (D5V3B)
  • immunohistochemistry; mouse; 1:100; loading ...; fig 6b
Cell Signaling Technology Cd274 antibody (Cell Signaling, 64988) was used in immunohistochemistry on mouse samples at 1:100 (fig 6b). Nat Commun (2020) ncbi
domestic rabbit monoclonal (D5V3B)
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 1c
Cell Signaling Technology Cd274 antibody (Cell Signaling, 64988) was used in immunohistochemistry - paraffin section on mouse samples (fig 1c). Oncoimmunology (2020) ncbi
BD Biosciences
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...; fig 4e
BD Biosciences Cd274 antibody (BD Biosciences, 558091) was used in flow cytometry on mouse samples (fig 4e). J Immunother Cancer (2022) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; 1:100; loading ...; fig s7c
BD Biosciences Cd274 antibody (BD, 558091) was used in flow cytometry on mouse samples at 1:100 (fig s7c). Cell Rep (2022) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; fig 2a
BD Biosciences Cd274 antibody (BD Pharmingen, 558091) was used in flow cytometry on mouse samples (fig 2a). Sci Adv (2022) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...; fig 6l
BD Biosciences Cd274 antibody (BD Pharmingen, 558091) was used in flow cytometry on mouse samples (fig 6l). Signal Transduct Target Ther (2021) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...; fig 5b
BD Biosciences Cd274 antibody (BD Biosciences, 558091) was used in flow cytometry on mouse samples (fig 5b). Oncoimmunology (2020) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...; fig 1e
BD Biosciences Cd274 antibody (BD, 558091) was used in flow cytometry on mouse samples (fig 1e). J Clin Invest (2020) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; loading ...; fig 2d
BD Biosciences Cd274 antibody (BD Biosciences, 558091) was used in flow cytometry on mouse samples (fig 2d). Sci Rep (2019) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; fig 5f
BD Biosciences Cd274 antibody (BD, MIH5) was used in flow cytometry on mouse samples (fig 5f). J Exp Med (2016) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; fig 1d
BD Biosciences Cd274 antibody (BD Biosciences, MIH5) was used in flow cytometry on mouse samples (fig 1d). J Immunol (2016) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; 1:200; fig s3
BD Biosciences Cd274 antibody (BD Biosciences, 558091) was used in flow cytometry on mouse samples at 1:200 (fig s3). Nat Commun (2016) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; fig 2
In order to characterize regulation of PD-L1 in melanoma by HDAC6, BD Biosciences Cd274 antibody (BDBioscience, 558091) was used in flow cytometry on mouse samples (fig 2). Mol Oncol (2016) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; fig 4
BD Biosciences Cd274 antibody (BD, MIH5) was used in flow cytometry on mouse samples (fig 4). Int J Oncol (2016) ncbi
rat monoclonal (MIH5)
  • flow cytometry; mouse; fig 6c
BD Biosciences Cd274 antibody (BD, MIH5) was used in flow cytometry on mouse samples (fig 6c). Sci Transl Med (2015) ncbi
ProSci
domestic rabbit polyclonal
  • western blot; mouse; fig 1c
ProSci Cd274 antibody (ProSci, 4059) was used in western blot on mouse samples (fig 1c). Sci Rep (2019) ncbi
Articles Reviewed
  1. Zhao X, Hu S, Zeng L, Liu X, Song Y, Zhang Y, et al. Irradiation combined with PD-L1-/- and autophagy inhibition enhances the antitumor effect of lung cancer via cGAS-STING-mediated T cell activation. iScience. 2022;25:104690 pubmed publisher
  2. Pi xf1 eros A, Kulkarni A, Gao H, Orr K, Glenn L, Huang F, et al. Proinflammatory signaling in islet β cells propagates invasion of pathogenic immune cells in autoimmune diabetes. Cell Rep. 2022;39:111011 pubmed publisher
  3. Huang J, Wang X, Li B, Shen S, Wang R, Tao H, et al. L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression. J Immunother Cancer. 2022;10: pubmed publisher
  4. Garnier L, Pick R, Montorfani J, Sun M, Brighouse D, Liaudet N, et al. IFN-γ-dependent tumor-antigen cross-presentation by lymphatic endothelial cells promotes their killing by T cells and inhibits metastasis. Sci Adv. 2022;8:eabl5162 pubmed publisher
  5. Taniguchi H, Caeser R, Chavan S, Zhan Y, Chow A, Manoj P, et al. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell Rep. 2022;39:110814 pubmed publisher
  6. Piao W, Li L, Saxena V, Iyyathurai J, Lakhan R, Zhang Y, et al. PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. Nat Commun. 2022;13:2176 pubmed publisher
  7. Saxena V, Piao W, Li L, Paluskievicz C, Xiong Y, Simon T, et al. Treg tissue stability depends on lymphotoxin beta-receptor- and adenosine-receptor-driven lymphatic endothelial cell responses. Cell Rep. 2022;39:110727 pubmed publisher
  8. El Sayes N, Walsh S, Vito A, Reihani A, Ask K, Wan Y, et al. IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity. Mol Ther Oncolytics. 2022;25:16-30 pubmed publisher
  9. Wedge M, Jennings V, Crupi M, Poutou J, Jamieson T, Pelin A, et al. Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy. Nat Commun. 2022;13:1898 pubmed publisher
  10. Xiong W, Gao X, Zhang T, Jiang B, Hu M, Bu X, et al. USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Nat Commun. 2022;13:1700 pubmed publisher
  11. van Vloten J, Matuszewska K, Minow M, Minott J, Santry L, Pereira M, et al. Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer. J Immunother Cancer. 2022;10: pubmed publisher
  12. Tang T, Huang X, Zhang G, Lu M, Hong Z, Wang M, et al. Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. J Immunother Cancer. 2022;10: pubmed publisher
  13. Gao X, Li W, Syed F, Yuan F, Li P, Yu Q. PD-L1 signaling in reactive astrocytes counteracts neuroinflammation and ameliorates neuronal damage after traumatic brain injury. J Neuroinflammation. 2022;19:43 pubmed publisher
  14. Kumar B, Adebayo A, Prasad M, Capitano M, Wang R, Bhat Nakshatri P, et al. Tumor collection/processing under physioxia uncovers highly relevant signaling networks and drug sensitivity. Sci Adv. 2022;8:eabh3375 pubmed publisher
  15. Kono M, Komatsuda H, Yamaki H, Kumai T, Hayashi R, Wakisaka R, et al. Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. Oncoimmunology. 2022;11:2021619 pubmed publisher
  16. Zou Y, Gan C, Xin Z, Zhang H, Zhang Q, Lee T, et al. Programmed Cell Death Protein 1 Blockade Reduces Glycogen Synthase Kinase 3β Activity and Tau Hyperphosphorylation in Alzheimer's Disease Mouse Models. Front Cell Dev Biol. 2021;9:769229 pubmed publisher
  17. Van Maldegem F, Valand K, Cole M, Patel H, Angelova M, Rana S, et al. Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. Nat Commun. 2021;12:5906 pubmed publisher
  18. Liu H, Pedros C, Kong K, Canonigo Balancio A, Xue W, Altman A. Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy. J Immunother Cancer. 2021;9: pubmed publisher
  19. Jiang Y, Yuan Y, Chen M, Li S, Bai J, Zhang Y, et al. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression. Theranostics. 2021;11:9162-9176 pubmed publisher
  20. Malenica I, Adam J, Corgnac S, Mezquita L, Auclin E, Damei I, et al. Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade. Nat Commun. 2021;12:5209 pubmed publisher
  21. Strait A, Woolaver R, Hall S, Young C, Karam S, Jimeno A, et al. Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma. Commun Biol. 2021;4:1005 pubmed publisher
  22. Liu Z, Wang T, She Y, Wu K, Gu S, Li L, et al. N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer. Mol Cancer. 2021;20:105 pubmed publisher
  23. Moreira T, Mangani D, Cox L, Leibowitz J, Lobo E, Oliveira M, et al. PD-L1+ and XCR1+ dendritic cells are region-specific regulators of gut homeostasis. Nat Commun. 2021;12:4907 pubmed publisher
  24. Xu P, Xiong W, Lin Y, Fan L, Pan H, Li Y. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression. Cell Death Dis. 2021;12:779 pubmed publisher
  25. Lu C, Liu Z, Klement J, Yang D, Merting A, Poschel D, et al. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape. J Immunother Cancer. 2021;9: pubmed publisher
  26. Kang C, Song C, Kim N, Nam R, Choi S, Yu J, et al. The Enhanced Inhibitory Effect of Estrogen on PD-L1 Expression Following Nrf2 Deficiency in the AOM/DSS Model of Colitis-Associated Cancer. Front Oncol. 2021;11:679324 pubmed publisher
  27. Van De Velde L, Allen E, Crawford J, Wilson T, Guy C, Russier M, et al. Neuroblastoma Formation Requires Unconventional CD4 T Cells and Arginase-1-Dependent Myeloid Cells. Cancer Res. 2021;81:5047-5059 pubmed publisher
  28. Hutton C, Heider F, Blanco Gómez A, Banyard A, Kononov A, Zhang X, et al. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. Cancer Cell. 2021;: pubmed publisher
  29. Bruand M, Barras D, Mina M, Ghisoni E, Morotti M, Lanitis E, et al. Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell Rep. 2021;36:109412 pubmed publisher
  30. Lauret Marie Joseph E, Kirilovsky A, Lecoester B, El Sissy C, Boullerot L, Rangan L, et al. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. J Immunother Cancer. 2021;9: pubmed publisher
  31. Zhang J, Qi J, Wei H, Lei Y, Yu H, Liu N, et al. TGFβ1 in Cancer-Associated Fibroblasts Is Associated With Progression and Radiosensitivity in Small-Cell Lung Cancer. Front Cell Dev Biol. 2021;9:667645 pubmed publisher
  32. Yan C, Saleh N, Yang J, Nebhan C, Vilgelm A, Reddy E, et al. Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. Mol Cancer. 2021;20:85 pubmed publisher
  33. Wu S, Fukumoto T, Lin J, Nacarelli T, Wang Y, Ong D, et al. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nat Cancer. 2021;2:189-200 pubmed publisher
  34. Go D, Lee S, Lee S, Woo S, Kim K, Kim K, et al. Programmed Death Ligand 1-Expressing Classical Dendritic Cells MitigateHelicobacter-Induced Gastritis. Cell Mol Gastroenterol Hepatol. 2021;12:715-739 pubmed publisher
  35. Zhou J, Pei X, Yang Y, Wang Z, Gao W, Ye R, et al. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma. J Immunother Cancer. 2021;9: pubmed publisher
  36. Gangoso E, Southgate B, Bradley L, Rus S, Gálvez Cancino F, McGivern N, et al. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion. Cell. 2021;184:2454-2470.e26 pubmed publisher
  37. Petty A, Dai R, Lapalombella R, Baiocchi R, Benson D, Li Z, et al. Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function. JCI Insight. 2021;6: pubmed publisher
  38. Liu X, Jiang J, Liao Y, Tang I, Zheng E, Qiu W, et al. Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. Adv Sci (Weinh). 2021;8:2002147 pubmed publisher
  39. Shen T, Liu J, Wang C, Rixiati Y, Li S, Cai L, et al. Targeting Erbin in B cells for therapy of lung metastasis of colorectal cancer. Signal Transduct Target Ther. 2021;6:115 pubmed publisher
  40. Sun Y, Jing J, Xu H, Xu L, Hu H, Tang C, et al. N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells. J Immunother Cancer. 2021;9: pubmed publisher
  41. Thanabalasuriar A, Chiang A, Morehouse C, Camara M, Hawkins S, Keller A, et al. PD-L1+ neutrophils contribute to injury-induced infection susceptibility. Sci Adv. 2021;7: pubmed publisher
  42. Liu J, Wang C, Cheng T, Rixiati Y, Ji C, Deng M, et al. Circadian Clock Disruption Suppresses PDL1+ Intraepithelial B Cells in Experimental Colitis and Colitis-Associated Colorectal Cancer. Cell Mol Gastroenterol Hepatol. 2021;12:251-276 pubmed publisher
  43. Chen J, Cao X, Li B, Zhao Z, Chen S, Lai S, et al. Warburg Effect Is a Cancer Immune Evasion Mechanism Against Macrophage Immunosurveillance. Front Immunol. 2020;11:621757 pubmed publisher
  44. Mondal T, Shivange G, Tihagam R, Lyerly E, Battista M, Talwar D, et al. Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies. EMBO Mol Med. 2021;13:e12716 pubmed publisher
  45. Furtado R, Chorro L, Zimmerman N, Guillen E, Spaulding E, Chin S, et al. Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses. Front Immunol. 2020;11:576743 pubmed publisher
  46. Alping P, Burman J, Lycke J, Frisell T, Piehl F. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Neurology. 2021;96:e1574-e1584 pubmed publisher
  47. Kharkwal S, Johndrow C, Veerapen N, Kharkwal H, Saavedra Avila N, Carreño L, et al. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy. Cancer Res. 2021;81:1788-1801 pubmed publisher
  48. Zhang H, Liu P, Zhang Y, Han L, Hu Z, Cai Z, et al. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer. FEBS Open Bio. 2021;11:911-920 pubmed publisher
  49. Wang Y, Mohseni M, Grauel A, Diez J, Guan W, Liang S, et al. SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms. Sci Rep. 2021;11:1399 pubmed publisher
  50. Ebelt N, Zuniga E, Marzagalli M, Zamloot V, Blazar B, Salgia R, et al. Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. Biomedicines. 2020;8: pubmed publisher
  51. Kasuga A, Semba T, Sato R, Nobusue H, Sugihara E, Takaishi H, et al. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice. Cancer Sci. 2021;112:1822-1838 pubmed publisher
  52. Zhao L, Hu S, Davila M, Yang J, Lin Y, Albanese J, et al. Coordinated co-migration of CCR10+ antibody-producing B cells with helper T cells for colonic homeostatic regulation. Mucosal Immunol. 2021;14:420-430 pubmed publisher
  53. Li Z, Zhang H, Huang Y, Huang J, Sun P, Zhou N, et al. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. Nat Commun. 2020;11:3806 pubmed publisher
  54. Ning Y, Ding J, Sun X, Xie Y, Su M, Ma C, et al. HDAC9 deficiency promotes tumor progression by decreasing the CD8+ dendritic cell infiltration of the tumor microenvironment. J Immunother Cancer. 2020;8: pubmed publisher
  55. Yamamoto K, Venida A, Yano J, Biancur D, Kakiuchi M, Gupta S, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581:100-105 pubmed publisher
  56. Liu X, Kong W, Peterson C, McGrail D, Hoang A, Zhang X, et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun. 2020;11:2135 pubmed publisher
  57. Zheng D, Gao F, Cheng Q, Bao P, Dong X, Fan J, et al. A vaccine-based nanosystem for initiating innate immunity and improving tumor immunotherapy. Nat Commun. 2020;11:1985 pubmed publisher
  58. von Roemeling C, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, et al. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun. 2020;11:1508 pubmed publisher
  59. Chaurasiya S, Yang A, Kang S, Lu J, Kim S, Park A, et al. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model. Oncoimmunology. 2020;9:1729300 pubmed publisher
  60. Aslan K, Turco V, Blobner J, Sonner J, Liuzzi A, Núñez N, et al. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Nat Commun. 2020;11:931 pubmed publisher
  61. Chen H, Cong X, Wu C, Wu X, Wang J, Mao K, et al. Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9+ T cells. Sci Adv. 2020;6:eaax4690 pubmed publisher
  62. Cohen G, Chandran P, Lorsung R, Tomlinson L, Sundby M, Burks S, et al. The Impact of Focused Ultrasound in Two Tumor Models: Temporal Alterations in the Natural History on Tumor Microenvironment and Immune Cell Response. Cancers (Basel). 2020;12: pubmed publisher
  63. Theivanthiran B, Evans K, Devito N, Plebanek M, Sturdivant M, Wachsmuth L, et al. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. J Clin Invest. 2020;130:2570-2586 pubmed publisher
  64. Liu Z, Wen J, Wu C, Hu C, Wang J, Bao Q, et al. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma. Aging (Albany NY). 2020;12:1213-1236 pubmed publisher
  65. Canel M, Taggart D, Sims A, Lonergan D, Waizenegger I, Serrels A. T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity. elife. 2020;9: pubmed publisher
  66. Khorooshi R, Marczynska J, Dieu R, Wais V, Hansen C, Kavan S, et al. Innate signaling within the central nervous system recruits protective neutrophils. Acta Neuropathol Commun. 2020;8:2 pubmed publisher
  67. Guo C, Allen B, Hiam K, Dodd D, Van Treuren W, Higginbottom S, et al. Depletion of microbiome-derived molecules in the host using Clostridium genetics. Science. 2019;366: pubmed publisher
  68. Leylek R, Alcántara Hernández M, Lanzar Z, Lüdtke A, Perez O, Reizis B, et al. Integrated Cross-Species Analysis Identifies a Conserved Transitional Dendritic Cell Population. Cell Rep. 2019;29:3736-3750.e8 pubmed publisher
  69. Shi L, Wang J, Ding N, Zhang Y, Zhu Y, Dong S, et al. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun. 2019;10:5421 pubmed publisher
  70. Brown C, Gudjonson H, Pritykin Y, Deep D, Lavallée V, Mendoza A, et al. Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity. Cell. 2019;179:846-863.e24 pubmed publisher
  71. Yan D, Wang J, Sun H, Zamani A, Zhang H, Chen W, et al. TIPE2 specifies the functional polarization of myeloid-derived suppressor cells during tumorigenesis. J Exp Med. 2020;217: pubmed publisher
  72. Benechet A, De Simone G, Di Lucia P, Cilenti F, Barbiera G, Le Bert N, et al. Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. Nature. 2019;574:200-205 pubmed publisher
  73. Findlay E, Currie A, Zhang A, Ovciarikova J, Young L, Stevens H, et al. Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy. Oncoimmunology. 2019;8:1608106 pubmed publisher
  74. Di Pilato M, Kim E, Cadilha B, Prüßmann J, Nasrallah M, Seruggia D, et al. Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. Nature. 2019;570:112-116 pubmed publisher
  75. Mizuno R, Sugiura D, Shimizu K, Maruhashi T, Watada M, Okazaki I, et al. PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation. Front Immunol. 2019;10:630 pubmed publisher
  76. Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, et al. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci Rep. 2019;9:6136 pubmed publisher
  77. Hammerich L, Marron T, Upadhyay R, Svensson Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25:814-824 pubmed publisher
  78. Binnewies M, Mujal A, Pollack J, Combes A, Hardison E, Barry K, et al. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. Cell. 2019;177:556-571.e16 pubmed publisher
  79. Poggio M, Hu T, Pai C, Chu B, BELAIR C, Chang A, et al. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019;177:414-427.e13 pubmed publisher
  80. Visekruna A, Hartmann S, Sillke Y, Glauben R, Fischer F, Raifer H, et al. Intestinal development and homeostasis require activation and apoptosis of diet-reactive T cells. J Clin Invest. 2019;129:1972-1983 pubmed publisher
  81. Rosenzweig N, Dvir Szternfeld R, Tsitsou Kampeli A, Keren Shaul H, Ben Yehuda H, Weill Raynal P, et al. PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nat Commun. 2019;10:465 pubmed publisher
  82. Ding L, Kim H, Wang Q, Kearns M, Jiang T, Ohlson C, et al. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018;25:2972-2980.e5 pubmed publisher
  83. Tordesillas L, Lozano Ojalvo D, Dunkin D, Mondoulet L, Agudo J, Merad M, et al. PDL2+ CD11b+ dermal dendritic cells capture topical antigen through hair follicles to prime LAP+ Tregs. Nat Commun. 2018;9:5238 pubmed publisher
  84. Sato Y, Bolzenius J, Eteleeb A, Su X, Maher C, Sehn J, et al. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade. JCI Insight. 2018;3: pubmed publisher
  85. Andre P, Denis C, Soulas C, Bourbon Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018;175:1731-1743.e13 pubmed publisher
  86. Wu F, Xu P, Chow A, Man S, Kruger J, Khan K, et al. Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. Br J Cancer. 2019;120:196-206 pubmed publisher
  87. Grohmann M, Wiede F, Dodd G, Gurzov E, Ooi G, Butt T, et al. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC. Cell. 2018;175:1289-1306.e20 pubmed publisher
  88. Umezu D, Okada N, Sakoda Y, Adachi K, Ojima T, Yamaue H, et al. Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment. Cancer Immunol Immunother. 2019;68:201-211 pubmed publisher
  89. Vuckovic S, Minnie S, Smith D, Gartlan K, Watkins T, Markey K, et al. Bone marrow transplantation generates T cell-dependent control of myeloma in mice. J Clin Invest. 2019;129:106-121 pubmed publisher
  90. Sang A, Danhorn T, Peterson J, Rankin A, O Connor B, Leach S, et al. Innate and adaptive signals enhance differentiation and expansion of dual-antibody autoreactive B cells in lupus. Nat Commun. 2018;9:3973 pubmed publisher
  91. Tilstra J, Avery L, Menk A, Gordon R, Smita S, Kane L, et al. Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted. J Clin Invest. 2018;128:4884-4897 pubmed publisher
  92. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity. 2018;49:264-274.e4 pubmed publisher
  93. Stathopoulou C, Gangaplara A, Mallett G, Flomerfelt F, Liniany L, Knight D, et al. PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells. Immunity. 2018;49:247-263.e7 pubmed publisher
  94. Li J, Byrne K, Yan F, Yamazoe T, Chen Z, Baslan T, et al. Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity. 2018;49:178-193.e7 pubmed publisher
  95. Vendetti F, Karukonda P, Clump D, Teo T, Lalonde R, Nugent K, et al. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest. 2018;128:3926-3940 pubmed publisher
  96. Du X, Wen J, Wang Y, Karmaus P, Khatamian A, Tan H, et al. Hippo/Mst signalling couples metabolic state and immune function of CD8α+ dendritic cells. Nature. 2018;558:141-145 pubmed publisher
  97. Hsu J, Xia W, Hsu Y, Chan L, Yu W, Cha J, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018;9:1908 pubmed publisher
  98. Crosby E, Wei J, Yang X, Lei G, Wang T, Liu C, et al. Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. Oncoimmunology. 2018;7:e1421891 pubmed publisher
  99. Hailemichael Y, Woods A, Fu T, He Q, Nielsen M, Hasan F, et al. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest. 2018;128:1338-1354 pubmed publisher
  100. Perry C, Muñoz Rojas A, Meeth K, Kellman L, Amezquita R, Thakral D, et al. Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. J Exp Med. 2018;215:877-893 pubmed publisher
  101. Tang H, Liang Y, Anders R, Taube J, Qiu X, Mulgaonkar A, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest. 2018;128:580-588 pubmed publisher
  102. Singh M, Vianden C, Cantwell M, Dai Z, Xiao Z, Sharma M, et al. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat Commun. 2017;8:1447 pubmed publisher
  103. Lynch A, Hawk W, Nylen E, Ober S, Autin P, Barber A. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma. Immunology. 2017;152:472-483 pubmed publisher
  104. van der Vlugt L, Obieglo K, Ozir Fazalalikhan A, Sparwasser T, Haeberlein S, Smits H. Schistosome-induced pulmonary B cells inhibit allergic airway inflammation and display a reduced Th2-driving function. Int J Parasitol. 2017;47:545-554 pubmed publisher
  105. Liu Z, Ravindranathan R, Kalinski P, Guo Z, Bartlett D. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017;8:14754 pubmed publisher
  106. Kogo H, Shimizu M, Negishi Y, Uchida E, Takahashi H. Suppression of murine tumour growth through CD8+ cytotoxic T lymphocytes via activated DEC-205+ dendritic cells by sequential administration of ?-galactosylceramide in vivo. Immunology. 2017;151:324-339 pubmed publisher
  107. Hartwig T, Montinaro A, von Karstedt S, Sevko A, Surinova S, Chakravarthy A, et al. The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2. Mol Cell. 2017;65:730-742.e5 pubmed publisher
  108. Huang A, Peng D, Guo H, Ben Y, Zuo X, Wu F, et al. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies. Sci Rep. 2017;7:42687 pubmed publisher
  109. Wu J, Sun L, Li H, Shen H, Zhai W, Yu Z, et al. Roles of programmed death protein 1/programmed death-ligand 1 in secondary brain injury after intracerebral hemorrhage in rats: selective modulation of microglia polarization to anti-inflammatory phenotype. J Neuroinflammation. 2017;14:36 pubmed publisher
  110. Tan S, Chowdhury S, Polak N, Gorrell M, Weninger W. Fibroblast activation protein is dispensable in the anti-influenza immune response in mice. PLoS ONE. 2017;12:e0171194 pubmed publisher
  111. Yanagita T, Murata Y, Tanaka D, Motegi S, Arai E, Daniwijaya E, et al. Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight. 2017;2:e89140 pubmed publisher
  112. Chamoto K, Chowdhury P, Kumar A, Sonomura K, Matsuda F, Fagarasan S, et al. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc Natl Acad Sci U S A. 2017;114:E761-E770 pubmed publisher
  113. Troegeler A, Mercier I, Cougoule C, Pietretti D, Colom A, Duval C, et al. C-type lectin receptor DCIR modulates immunity to tuberculosis by sustaining type I interferon signaling in dendritic cells. Proc Natl Acad Sci U S A. 2017;114:E540-E549 pubmed publisher
  114. Connor L, Tang S, Cognard E, Ochiai S, Hilligan K, Old S, et al. Th2 responses are primed by skin dendritic cells with distinct transcriptional profiles. J Exp Med. 2017;214:125-142 pubmed publisher
  115. Khan S, Woodruff E, Trapecar M, Fontaine K, Ezaki A, Borbet T, et al. Dampened antiviral immunity to intravaginal exposure to RNA viral pathogens allows enhanced viral replication. J Exp Med. 2016;213:2913-2929 pubmed
  116. Cummings R, Barbet G, Bongers G, Hartmann B, Gettler K, Muniz L, et al. Different tissue phagocytes sample apoptotic cells to direct distinct homeostasis programs. Nature. 2016;539:565-569 pubmed publisher
  117. Wang S, Campos J, Gallotta M, Gong M, Crain C, Naik E, et al. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc Natl Acad Sci U S A. 2016;113:E7240-E7249 pubmed
  118. Jirmo A, Daluege K, Happle C, Albrecht M, Dittrich A, Busse M, et al. IL-27 Is Essential for Suppression of Experimental Allergic Asthma by the TLR7/8 Agonist R848 (Resiquimod). J Immunol. 2016;197:4219-4227 pubmed
  119. Starobinets H, Ye J, Broz M, Barry K, Goldsmith J, Marsh T, et al. Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment. J Clin Invest. 2016;126:4417-4429 pubmed publisher
  120. Klotz L, Kuzmanov I, Hucke S, Gross C, Posevitz V, Dreykluft A, et al. B7-H1 shapes T-cell-mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity. Proc Natl Acad Sci U S A. 2016;113:E6182-E6191 pubmed
  121. Shi L, Fu T, Guan B, Chen J, Blando J, Allison J, et al. Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined ?-CTLA-4+?-PD-1 therapy. Nat Commun. 2016;7:12335 pubmed publisher
  122. Pizzolla A, Oh D, Luong S, Prickett S, Henstridge D, Febbraio M, et al. High Fat Diet Inhibits Dendritic Cell and T Cell Response to Allergens but Does Not Impair Inhalational Respiratory Tolerance. PLoS ONE. 2016;11:e0160407 pubmed publisher
  123. Chow K, Delconte R, Huntington N, Tarlinton D, Sutherland R, Zhan Y, et al. Innate Allorecognition Results in Rapid Accumulation of Monocyte-Derived Dendritic Cells. J Immunol. 2016;197:2000-8 pubmed publisher
  124. Seifert A, Zeng S, Zhang J, Kim T, Cohen N, Beckman M, et al. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res. 2017;23:454-465 pubmed publisher
  125. Baptista M, Keszei M, Oliveira M, Sunahara K, Andersson J, Dahlberg C, et al. Deletion of Wiskott-Aldrich syndrome protein triggers Rac2 activity and increased cross-presentation by dendritic cells. Nat Commun. 2016;7:12175 pubmed publisher
  126. Zhang Y, Velez Delgado A, Mathew E, Li D, Mendez F, Flannagan K, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut. 2017;66:124-136 pubmed publisher
  127. Iwasaki Y, Sugita S, Mandai M, Yonemura S, Onishi A, Ito S, et al. Differentiation/Purification Protocol for Retinal Pigment Epithelium from Mouse Induced Pluripotent Stem Cells as a Research Tool. PLoS ONE. 2016;11:e0158282 pubmed publisher
  128. Saha A, O Connor R, Thangavelu G, Lovitch S, Dandamudi D, Wilson C, et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016;126:2642-60 pubmed publisher
  129. Mall C, Sckisel G, Proia D, Mirsoian A, Grossenbacher S, Pai C, et al. Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology. 2016;5:e1075114 pubmed
  130. Seifert L, Werba G, Tiwari S, Giao Ly N, Alothman S, Alqunaibit D, et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature. 2016;532:245-9 pubmed publisher
  131. Seifert L, Werba G, Tiwari S, Giao Ly N, Nguy S, Alothman S, et al. Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. Gastroenterology. 2016;150:1659-1672.e5 pubmed publisher
  132. Haribhai D, Ziegelbauer J, Jia S, Upchurch K, Yan K, Schmitt E, et al. Alternatively Activated Macrophages Boost Induced Regulatory T and Th17 Cell Responses during Immunotherapy for Colitis. J Immunol. 2016;196:3305-17 pubmed publisher
  133. Foy S, Sennino B, dela Cruz T, Cote J, Gordon E, Kemp F, et al. Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice. PLoS ONE. 2016;11:e0150084 pubmed publisher
  134. Azpilikueta A, Agorreta J, Labiano S, Pérez Gracia J, Sánchez Paulete A, Aznar M, et al. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. J Thorac Oncol. 2016;11:524-36 pubmed publisher
  135. Aloulou M, Carr E, Gador M, Bignon A, Liblau R, Fazilleau N, et al. Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells. Nat Commun. 2016;7:10579 pubmed publisher
  136. M L, P P, T K, M P, E S, J P, et al. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Mol Oncol. 2016;10:735-750 pubmed publisher
  137. Mikyšková R, Štěpánek I, Indrová M, Bieblová J, Šímová J, Truxová I, et al. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. Int J Oncol. 2016;48:953-64 pubmed publisher
  138. Patel M, Jacobson B, Ji Y, Drees J, Tang S, Xiong K, et al. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. Oncotarget. 2015;6:33165-77 pubmed publisher
  139. Ngiow S, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015;75:3800-11 pubmed publisher
  140. Imai Y, Ayithan N, Wu X, Yuan Y, Wang L, Hwang S. Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells. J Immunol. 2015;195:421-5 pubmed publisher
  141. Tkachev V, Goodell S, Opipari A, Hao L, Franchi L, Glick G, et al. Programmed death-1 controls T cell survival by regulating oxidative metabolism. J Immunol. 2015;194:5789-800 pubmed publisher
  142. Liechtenstein T, Perez Janices N, Blanco Luquin I, Goyvaerts C, Schwarze J, Dufait I, et al. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology. 2014;3:e945378 pubmed
  143. Hu Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015;7:279ra41 pubmed publisher
  144. Okamura T, Sumitomo S, Morita K, Iwasaki Y, Inoue M, Nakachi S, et al. TGF-β3-expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses. Nat Commun. 2015;6:6329 pubmed publisher
  145. McKay J, Egan R, Yammani R, Chen L, Shin T, Yagita H, et al. PD-1 suppresses protective immunity to Streptococcus pneumoniae through a B cell-intrinsic mechanism. J Immunol. 2015;194:2289-99 pubmed publisher
  146. Jing W, Gershan J, Weber J, Tlomak D, McOlash L, Sabatos Peyton C, et al. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer. 2015;3:2 pubmed publisher
  147. Lei G, Zhang C, Lee C. Myeloid-derived suppressor cells impair alveolar macrophages through PD-1 receptor ligation during Pneumocystis pneumonia. Infect Immun. 2015;83:572-82 pubmed publisher
  148. Tassi I, Claudio E, Wang H, Tang W, Ha H, Saret S, et al. The NF-κB regulator Bcl-3 governs dendritic cell antigen presentation functions in adaptive immunity. J Immunol. 2014;193:4303-11 pubmed publisher
  149. Zhu Y, Knolhoff B, Meyer M, Nywening T, West B, Luo J, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74:5057-69 pubmed publisher
  150. Ramakrishnan R, Tyurin V, Tuyrin V, Veglia F, Condamine T, Amoscato A, et al. Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol. 2014;192:2920-31 pubmed publisher
  151. Chang S, Kohrt H, Maecker H. Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother. 2014;63:713-9 pubmed publisher
  152. Barsoum I, Smallwood C, Siemens D, Graham C. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74:665-74 pubmed publisher
  153. Bodhankar S, Chen Y, Vandenbark A, Murphy S, Offner H. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1. J Neuroinflammation. 2013;10:111 pubmed publisher
  154. Van Der Werf N, Redpath S, Azuma M, Yagita H, Taylor M. Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection. PLoS Pathog. 2013;9:e1003215 pubmed publisher
  155. Charles E, Joshi S, Ash J, Fox B, Farris A, Bzik D, et al. CD4 T-cell suppression by cells from Toxoplasma gondii-infected retinas is mediated by surface protein PD-L1. Infect Immun. 2010;78:3484-92 pubmed publisher
  156. Tasso R, Augello A, Boccardo S, Salvi S, Carida M, Postiglione F, et al. Recruitment of a host's osteoprogenitor cells using exogenous mesenchymal stem cells seeded on porous ceramic. Tissue Eng Part A. 2009;15:2203-12 pubmed publisher
  157. Saito K, Torii M, Ma N, Tsuchiya T, Wang L, Hori T, et al. Differential regulatory function of resting and preactivated allergen-specific CD4+ CD25+ regulatory T cells in Th2-type airway inflammation. J Immunol. 2008;181:6889-97 pubmed
  158. Sheng H, Wang Y, Jin Y, Zhang Q, Zhang Y, Wang L, et al. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res. 2008;18:846-57 pubmed publisher
  159. Kanzato H, Fujiwara S, Ise W, Kaminogawa S, Sato R, Hachimura S. Lactobacillus acidophilus strain L-92 induces apoptosis of antigen-stimulated T cells by modulating dendritic cell function. Immunobiology. 2008;213:399-408 pubmed publisher
  160. Kuipers H, Muskens F, Willart M, Hijdra D, van Assema F, Coyle A, et al. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur J Immunol. 2006;36:2472-82 pubmed
  161. Schoop R, Wahl P, Le Hir M, Heemann U, Wang M, Wuthrich R. Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells. Nephrol Dial Transplant. 2004;19:2713-20 pubmed
  162. Smith P, Walsh C, Mangan N, Fallon R, Sayers J, McKenzie A, et al. Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages. J Immunol. 2004;173:1240-8 pubmed